» Articles » PMID: 29862008

Glycemic Control and Bone Turnover in Older Mexican Americans with Type 2 Diabetes

Overview
Journal J Osteoporos
Publisher Wiley
Specialty Orthopedics
Date 2018 Jun 5
PMID 29862008
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Altered bone quality, caused by underlying metabolic changes of type 2 diabetes (T2D), has been hypothesized to cause altered bone strength and turnover leading to increased fracture risk in T2D patients. Current understanding about changes in bone turnover markers in T2D patients is mainly based on studies focused on Caucasian men and women. However, Hispanic populations have the highest prevalence of both T2D and osteoporosis in the US. We investigated associations of glycemic control (in terms of glycated hemoglobin [HbA1c]) and bone turnover rate in 69 older (≥50 years) Mexican American Cameron County Hispanic Cohort (CCHC) participants with T2D. Multivariable analyses were conducted to assess the associations between HbA1c (%), serum osteocalcin (OC), and serum sclerostin. In agreement with published reports from other racial/ethnic populations, our study found that lower bone turnover (indicated by lower serum OC) occurred in Mexican American men with T2D who had poorer glycemic control. For the women in our study, we found no significant association between glycemic control and OC. In contrast, HbA1c was positively associated with sclerostin for women, with near significance ( = 0.07), while no association was found in men. We recommend screening Mexican American individuals with T2D, specifically those with poor glycemic control, for bone loss and fracture risk.

Citing Articles

Peroxisome proliferator activated receptor-γ in osteoblasts controls bone formation and fat mass by regulating sclerostin expression.

Kim S, Seward A, Garcia-Diaz J, Alekos N, Gould N, Aja S iScience. 2023; 26(7):106999.

PMID: 37534168 PMC: 10391670. DOI: 10.1016/j.isci.2023.106999.


Correlation Between Mean Amplitude of Glycemic Excursion and Bone Turnover Markers in Patients with Type 2 Diabetes: A Cross-Sectional Study.

Yang J, Zheng C, Wang Y, Yang L, Liu L Diabetes Metab Syndr Obes. 2023; 16:397-407.

PMID: 36798908 PMC: 9926982. DOI: 10.2147/DMSO.S388919.


Endocrine Functions of Sclerostin.

Riddle R Curr Opin Endocr Metab Res. 2023; 28.

PMID: 36713826 PMC: 9881182. DOI: 10.1016/j.coemr.2022.100433.


The role of advanced glycation end products in fracture risk assessment in postmenopausal type 2 diabetic patients.

Gao L, Liu C, Hu P, Wang N, Bao X, Wang B Front Endocrinol (Lausanne). 2022; 13:1013397.

PMID: 36578954 PMC: 9790927. DOI: 10.3389/fendo.2022.1013397.


Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies.

Hidayat K, Fang Q, Shi B, Qin L Osteoporos Int. 2021; 32(9):1693-1704.

PMID: 33860816 DOI: 10.1007/s00198-021-05934-2.


References
1.
Gundberg C, Looker A, Nieman S, Calvo M . Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. Bone. 2003; 31(6):703-8. DOI: 10.1016/s8756-3282(02)00902-x. View

2.
Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y . Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab. 1997; 82(9):2915-20. DOI: 10.1210/jcem.82.9.4258. View

3.
Singh S, Kumar D, Lal A . Serum Osteocalcin as a Diagnostic Biomarker for Primary Osteoporosis in Women. J Clin Diagn Res. 2015; 9(8):RC04-7. PMC: 4576601. DOI: 10.7860/JCDR/2015/14857.6318. View

4.
Heilmeier U, Carpenter D, Patsch J, Harnish R, Joseph G, Burghardt A . Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures. Osteoporos Int. 2015; 26(4):1283-93. DOI: 10.1007/s00198-014-2988-7. View

5.
Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T . Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int. 2009; 85(3):228-34. DOI: 10.1007/s00223-009-9272-4. View